Kiniksa Pharmaceuticals International Business Summary

Kiniksa Pharmaceuticals International, plc (KNSA) is a commercial-stage biopharmaceutical company that generates revenue primarily through the direct sale of its flagship product, ARCALYST (rilonacept), the first and only FDA-approved therapy for recurrent pericarditis. The company’s business model is centered on the commercialization of orphan and specialty cardiovascular treatments, supplemented by a high-growth pipeline of immune-modulating assets including KPL-387 (rilonacept liquid formulation) and KPL-1161. Kiniksa reported $677.6 million in net product revenue for 2025—a 62% year-over-year increase—and has issued 2026 revenue guidance of $900 million to $920 million. Within the competitive landscape, Kiniksa contends with large-cap biotechs and rare disease specialists such as Amgen, BridgeBio Pharma, and Argenx; however, it maintains a dominant market position as the standard-of-care leader in the recurrent pericarditis space, currently capturing approximately 18% of the multiple-recurrence patient population with significant expansion underway into first-recurrence segments. The company was founded in 2015 by Chairman and CEO Sanj K. Patel, the former founder and CEO of Synageva BioPharma, which he famously led to a $9.5 billion acquisition by Alexion Pharmaceuticals. The leadership team is composed of industry veterans with deep pedigrees in rare disease commercialization, including Chief Operating Officer Ross Moat, who was appointed in January 2026 to oversee global commercial operations, and Chief Strategy Officer Eben Tessari, who previously served as COO and leads the company’s AI and business development initiatives. Other key executives include Chief Medical Officer John Paolini and Chief Technical Officer Mei Jang. Kiniksa is backed by high-profile institutional investors, most notably Baker Bros. Advisors, whose Managing Director M. Cantey Boyd serves on the board alongside Lead Director Felix Baker. The board also features seasoned experts like Dr. Richard Levy, formerly the Executive Vice President and Chief Drug Development Officer at Incyte.